Record $11.6 Billion Fuels European Healthtech Boom
In 2024, European healthtech companies attracted a record-breaking $11.6 billion in funding, driven by AI, biotech, and big data advancements that promise to revolutionize patient care, address health disparities, and improve global health outcomes.
Record $11.6 Billion Fuels European Healthtech Boom
In 2024, European healthtech companies attracted a record-breaking $11.6 billion in funding, driven by AI, biotech, and big data advancements that promise to revolutionize patient care, address health disparities, and improve global health outcomes.
Progress
52% Bias Score
GLP-1 Drug Adherence: Cost, Side Effects, and Income Disparities
A JAMA Network Open study reveals that 65% of patients without diabetes stopped using GLP-1 weight loss drugs within a year, compared to 46% of those with Type 2 diabetes; side effects and cost were the main reasons, while higher income and weight loss correlated with continued use; Noom's layoffs e...
GLP-1 Drug Adherence: Cost, Side Effects, and Income Disparities
A JAMA Network Open study reveals that 65% of patients without diabetes stopped using GLP-1 weight loss drugs within a year, compared to 46% of those with Type 2 diabetes; side effects and cost were the main reasons, while higher income and weight loss correlated with continued use; Noom's layoffs e...
Progress
40% Bias Score
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Progress
44% Bias Score
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
Progress
40% Bias Score
JPMorgan Health Care Conference: Major Acquisitions and Shifting Market Dynamics
The JPMorgan Health Care Conference in San Francisco saw Johnson & Johnson acquire Intra-Cellular Therapies for \$14.6 billion, exceeding 2024's largest deal; other significant acquisitions were announced by Eli Lilly and GSK, while Moderna and Eli Lilly lowered their 2025 sales guidance. Increased ...
JPMorgan Health Care Conference: Major Acquisitions and Shifting Market Dynamics
The JPMorgan Health Care Conference in San Francisco saw Johnson & Johnson acquire Intra-Cellular Therapies for \$14.6 billion, exceeding 2024's largest deal; other significant acquisitions were announced by Eli Lilly and GSK, while Moderna and Eli Lilly lowered their 2025 sales guidance. Increased ...
Progress
44% Bias Score
GLP-1 Weight Loss Drugs May Reduce Breast Cancer Treatment Efficacy
A study of hundreds of women with triple-negative breast cancer found that those taking GLP-1 weight-loss drugs like Ozempic and Wegovy had significantly lower remission rates (28% vs 63%) after treatment, suggesting interference with chemotherapy and immunotherapy effectiveness.
GLP-1 Weight Loss Drugs May Reduce Breast Cancer Treatment Efficacy
A study of hundreds of women with triple-negative breast cancer found that those taking GLP-1 weight-loss drugs like Ozempic and Wegovy had significantly lower remission rates (28% vs 63%) after treatment, suggesting interference with chemotherapy and immunotherapy effectiveness.
Progress
52% Bias Score